Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The effects of cyclophosphamide on in vitro correlates of tumor immunity

Steele, G. ; Sjögren, H. O. LU and Ankerst, J. LU orcid (1974) In International Journal of Cancer 14(6). p.743-752
Abstract

The effects of cyclophosphamide (CY) on tumor immunity against isografts of rat sarcomas induced by polyoma virus were studied using in vitro techniques. Groups of sarcoma‐bearing animals received CY (250 mg/kg intraperitoneally 11 days after isografting) CY (150 mg/kg IP 8 days after isografting), or IP injections of 0.9% NaCl. In control rats tumor growth was progressive. All CY‐treated animals showed transient tumor regression of at least 50% of their pretreatment tumor volume. Despite a drastic depression in numbers of blood leukocytes as well as lymph‐node cells following CY treatment, animals treated with 150 mg/kg CY were shown to have blood lymphocyte and lymph‐node cell cytotoxicity in vitro against plated sarcoma target cells... (More)

The effects of cyclophosphamide (CY) on tumor immunity against isografts of rat sarcomas induced by polyoma virus were studied using in vitro techniques. Groups of sarcoma‐bearing animals received CY (250 mg/kg intraperitoneally 11 days after isografting) CY (150 mg/kg IP 8 days after isografting), or IP injections of 0.9% NaCl. In control rats tumor growth was progressive. All CY‐treated animals showed transient tumor regression of at least 50% of their pretreatment tumor volume. Despite a drastic depression in numbers of blood leukocytes as well as lymph‐node cells following CY treatment, animals treated with 150 mg/kg CY were shown to have blood lymphocyte and lymph‐node cell cytotoxicity in vitro against plated sarcoma target cells comparable to untreated sarcoma‐bearing animals. Sera obtained from sarcoma‐bearing rats prior to CY treatment specifically blocked lymphocyte cytotoxicity against sarcoma target cells. After CY treatment serum blocking activity could not be demonstrated during the period of tumor regression, but reappeared in parallel with tumor regrowth. Antibodies cytotoxic to sarcoma target cells when homologous complement was added could not be demonstrated in sera obtained from animals before CY treatment, but were present after treatment during tumor remission. Following CY treatment, sera obtained from treated animals, when mixed with blocking sera from control animals, could counteract or unblock the blocking activity of tumor‐bearer sera. Unblocking capacity was present only in sera obtained during CY‐induced tumor remission. Serum IgG concentration was significantly and temporarily decreased after CY treatment.

(Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Cancer
volume
14
issue
6
pages
743 - 752
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:4377004
  • scopus:0016316588
ISSN
0020-7136
DOI
10.1002/ijc.2910140608
language
English
LU publication?
yes
id
f98f21f9-45b4-4393-a9de-8be80987d0bd
date added to LUP
2021-01-22 13:10:07
date last changed
2024-01-03 05:38:01
@article{f98f21f9-45b4-4393-a9de-8be80987d0bd,
  abstract     = {{<p>The effects of cyclophosphamide (CY) on tumor immunity against isografts of rat sarcomas induced by polyoma virus were studied using in vitro techniques. Groups of sarcoma‐bearing animals received CY (250 mg/kg intraperitoneally 11 days after isografting) CY (150 mg/kg IP 8 days after isografting), or IP injections of 0.9% NaCl. In control rats tumor growth was progressive. All CY‐treated animals showed transient tumor regression of at least 50% of their pretreatment tumor volume. Despite a drastic depression in numbers of blood leukocytes as well as lymph‐node cells following CY treatment, animals treated with 150 mg/kg CY were shown to have blood lymphocyte and lymph‐node cell cytotoxicity in vitro against plated sarcoma target cells comparable to untreated sarcoma‐bearing animals. Sera obtained from sarcoma‐bearing rats prior to CY treatment specifically blocked lymphocyte cytotoxicity against sarcoma target cells. After CY treatment serum blocking activity could not be demonstrated during the period of tumor regression, but reappeared in parallel with tumor regrowth. Antibodies cytotoxic to sarcoma target cells when homologous complement was added could not be demonstrated in sera obtained from animals before CY treatment, but were present after treatment during tumor remission. Following CY treatment, sera obtained from treated animals, when mixed with blocking sera from control animals, could counteract or unblock the blocking activity of tumor‐bearer sera. Unblocking capacity was present only in sera obtained during CY‐induced tumor remission. Serum IgG concentration was significantly and temporarily decreased after CY treatment.</p>}},
  author       = {{Steele, G. and Sjögren, H. O. and Ankerst, J.}},
  issn         = {{0020-7136}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{743--752}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{International Journal of Cancer}},
  title        = {{The effects of cyclophosphamide on in vitro correlates of tumor immunity}},
  url          = {{http://dx.doi.org/10.1002/ijc.2910140608}},
  doi          = {{10.1002/ijc.2910140608}},
  volume       = {{14}},
  year         = {{1974}},
}